MedTrace Logo

Effects of Low Dose Naltrexone in Fibromyalgia

NCT00568555 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2015-10-21

Study results available
· View outcomes & findings →

Summary

Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.

Conditions

  • Fibromyalgia
  • Persian Gulf Syndrome

Interventions

DRUG

Low Dose Naltrexone

3-4.5mg Naltrexone once daily

DRUG

Placebo - sugar pill

Placebo pill once daily

Sponsors & Collaborators

Principal Investigators

  • Jarred Younger · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568555 on ClinicalTrials.gov